References
- Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for ST1-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938— 42.
- Imatinib mesylate. Am J Health Syst Pharm 2001; 58: 2241–2.
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl I Med 2001; 344: 1031–7.
- Pietras K, Ostman A, Sjoqist M, et al. Inhibition of platelet derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929— 34.
- Ebnoether M, Stentoft J, Ford J, et al. Cerebral edema as a possible complication of treatment with imatinib. Lancet 2002; 359: 1751–2.
- Sawyers CL, Hochhaus A, Feldmen E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: result of a phase II study. Blood 2002; 99: 3530— 9.
- Fischer T, Reifenrath C, Hess GR, et al. Safety and efficacy of ST1-571 (imatinib mesylate) in pateints with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia 2002; 6: 1220–8.
- Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl I Med 2001; 344: 1038— 42.
- Heuchel R, Berg A, Tallquist M, et al. Plateletderi ved growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinosito1-3'kinase signaling. Proc Natl Acad Sci USA 1999; 96: 11410–15.